Acute Myeloid Leukemia

Fillmore has investigated the impact of non-malignant comorbidities and patient vulnerability on outcomes for individuals with acute myeloid leukemia. His research demonstrates that frailty, psychiatric disorders, and substance use are significant predictors of decreased survival and lower remission rates when using standard therapies. Additionally, his work highlights a heightened risk of arterial thromboembolism among patients with acute leukemia compared to other cancer populations.